Embedded on the page ‘We build knowledge’
A lineup of experts shared their insights on different aspects of raising capital during a well-attended seminar on 1 September arranged by SwedenBIO’s Finance Working Group in cooperation with Redeye.
Top management level in companies and organisations within the life science sector, as well as companies supporting the life science sector, such as service providers and investors are welcome to fill out the survey.
On March 8, 2023 SwedenBIO launched the 2023 edition of the large, recurring mapping of the Swedish pharmaceutical pipeline.
On March 8, SwedenBIO launches the long-awaited 2023 edition of the large, recurring mapping of the Swedish pharmaceutical pipeline.
At the SwedenBIO Summit December 6, our science relations manager Maja Neiman revealed some preliminary results from this year’s life science barometer. A comprehensive analysis will be published in the next edition of the The Swedish Drug Discovery and Development Pipeline report, coming in February 2023.
Det sjunde och sista avsnittet av MDR-Podden har nu kommit ut och ger en tillbakablick på säsongen som varit och vad vi nu kan säga om medical device regulation.
How to create sustainable trading on the stock exchange
The life science sector is one of the strongest for listed small companies in Sweden. At the same time, the competition in the sector is fierce and it is necessary to work with the issues that affect share trading. A well-functioning share trading is important for creating growth in small and medium-sized companies.
Offer to you as an incubator company
Life for startup companies was not without challenges before the effects of the corona crisis hit, and the situation is now tough for many smaller companies. Now we want to contribute to building Sweden’s next generation of life science companies strong, for future export revenue and innovation power. Startup companies with up to four employees must be members of SwedenBIO for an annual fee of SEK 1,000.
Brännpunkt Life Science is an interview series in collaboration with DNB Sweden that focuses the magnifying glass on the intersection between innovation, capital and health. In the first part, we meet Adam Kostyal, European head of listing at Nasdaq, who looks at how the stock market year looked for the sector, talks about the impact of the pandemic and shares his predictions for the future.
